XETRSBX
Market cap25mUSD
Dec 23, Last price
4.36EUR
1D
6.34%
1Q
-26.60%
Name
SynBiotic SE
Chart & Performance
P/E
—
P/S
6.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.91%
Rev. gr., 5y
%
Revenues
4m
-52.71%
Net income
-11m
L-56.36%
CFO
-3m
L-58.20%
Profile
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 3,861 -52.71% | 8,166 -9.91% | 9,064 65.63% | |||
Cost of revenue | 3,760 | 7,269 | 7,645 | |||
Unusual Expense (Income) | ||||||
NOPBT | 101 | 897 | 1,419 | |||
NOPBT Margin | 2.61% | 10.98% | 15.65% | |||
Operating Taxes | (135) | (189) | (290) | |||
Tax Rate | ||||||
NOPAT | 236 | 1,086 | 1,708 | |||
Net income | (10,631) -56.36% | (24,362) 86.40% | (13,070) 1,384.53% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,157 | 4,200 | 7,014 | |||
BB yield | -22.23% | -9.74% | -7.66% | |||
| Debt | ||||||
Debt current | 787 | 902 | 7 | |||
Long-term debt | 3,411 | 4,262 | 1,876 | |||
Deferred revenue | 1 | 2,671 | ||||
Other long-term liabilities | 8,650 | 8,418 | 12,744 | |||
Net debt | 4,691 | 4,186 | (1,559) | |||
| Cash flow | ||||||
Cash from operating activities | (2,924) | (6,996) | (5,144) | |||
CAPEX | (19) | (478) | (366) | |||
Cash from investing activities | (733) | (68) | (3,059) | |||
Cash from financing activities | 2,780 | 4,828 | 5,415 | |||
FCF | 1,638 | 1,358 | (5,785) | |||
| Balance | ||||||
Cash | 2,068 | 3,034 | 5,239 | |||
Long term investments | (2,562) | (2,057) | (1,797) | |||
Excess cash | 569 | 2,989 | ||||
Stockholders' equity | (44,072) | (33,212) | (8,170) | |||
Invested Capital | 71,729 | 68,817 | 61,145 | |||
ROIC | 0.34% | 1.67% | 4.02% | |||
ROCE | 0.36% | 2.51% | 2.66% | |||
| EV | ||||||
Common stock shares outstanding | 4,749 | 4,132 | 3,105 | |||
Price | 2.99 -71.36% | 10.44 -64.60% | 29.49 | |||
Market cap | 14,200 -67.08% | 43,137 -52.88% | 91,552 | |||
EV | 18,429 | 47,520 | 91,718 | |||
EBITDA | 4,654 | 19,409 | 9,734 | |||
EV/EBITDA | 3.96 | 2.45 | 9.42 | |||
Interest | 195 | 189 | 47 | |||
Interest/NOPBT | 193.52% | 21.06% | 3.29% | |||